GAS_Vaccinology__Capturing_Global_Vaccine_Antigen_Diversity-sc-4137
GAS_Vaccinology__Capturing_Global_Vaccine_Antigen_Diversity
This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/
This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing.